Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1FED 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Hot Flashes 2Neoplasms 1Depressive Disorder, Major 1Depression 1

Interventions

Therapeutics 28Psychiatric Rehabilitation 21Surveys and Questionnaires 14Cognitive Behavioral Therapy 12Psilocybin 8Methods 8Ketamine 8Early Intervention, Educational 8Saline Solution 7Yoga 6Mindfulness-Based Cognitive Therapy 6Interviews as Topic 6Esketamine 6Psychosocial Intervention 5Mindfulness 5Escitalopram 5Behavior Therapy 5Methylphenidate 4Exercise Therapy 4Exercise 4Educational Status 4Counseling 4Control Groups 4Acupuncture Therapy 4Standard of Care 3Psychotherapy 3Palliative Care 3Niacin 3Mindfulness-Based Stress Reduction 3Melatonin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Depression × Citalopram × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡